Open AccessFluBlok, a recombinant hemagglutinin influenza vaccine
Author(s) -
Cox Ma M.J.,
Patriarca Peter A.,
Treanor John
Publication year - 2008
Publication title -
influenza and other respiratory viruses
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.743
H-Index - 57
eISSN - 1750-2659
pISSN - 1750-2640
DOI - 10.1111/j.1750-2659.2008.00053.x
Subject(s) - virology , hemagglutinin (influenza) , influenza vaccine , recombinant dna , influenza a virus , microbiology and biotechnology , medicine , vaccination , biology , virus , genetics , gene
FluBlok, a recombinant trivalent hemagglutinin (HA) vaccine produced in insect cell culture using the baculovirus expression system, provides an attractive alternative to the current egg‐based trivalent inactivated influenza vaccine (TIV) manufacturing process. FluBlok contains three times more HA than TIV and does not contain egg‐protein or preservatives. This review discusses the four main clinical studies that were used to support licensure of FluBlok under the ‘Accelerated Approval’ mechanism in the United States.